Post Antibiotic Effect

The post-antibiotic effect (PAE) is the persistent suppression of bacterial growth after brief exposure to an antibiotic when drug concentration has fallen under the MIC or been removed. It is measured as the difference in time (T minus C) for the exposed culture and an unexposed control to grow by a defined amount. It explains why drugs with short half-lives can be dosed at long intervals.

Mechanism. Proposed mechanisms include non-lethal damage to cell structures or enzymes that takes time to repair, persistence of the drug at the target, and slow recovery of protein synthesis or DNA replication. The duration depends on the drug, organism, concentration and exposure time.

Related effects. The post-antibiotic sub-MIC effect (PA-SME) is delayed regrowth when organisms previously exposed to the drug meet sub-MIC concentrations. Post-antibiotic leucocyte enhancement (PALE) is increased phagocytosis of antibiotic-exposed bacteria. In vivo PAE is usually longer than in vitro, partly through these effects.

• Long PAE (2 to 6 hours or more): aminoglycosides and fluoroquinolones against Gram-negative bacilli; most protein synthesis and nucleic acid inhibitors against Gram-positives; rifampicin; tetracyclines; macrolides and clindamycin against some organisms.
• Short or absent PAE: beta-lactams against Gram-negative bacilli (apart from carbapenems against Pseudomonas aeruginosa); beta-lactams have a modest PAE (1 to 2 hours) against Gram-positive cocci.
• Variable: glycopeptides (modest PAE of 1 to 4 hours), daptomycin (several hours).

Applications.

• Supports once-daily aminoglycoside dosing, with a drug-free period that reduces toxicity.
• Supports less frequent dosing of fluoroquinolones and azithromycin.
• Explains why beta-lactams require near-continuous exposure against Gram-negative bacteria.
• Informs extended-interval strategies, intermittent therapy and short-course regimens.

Limits. The PAE is not constant and is shortened by low inoculum, immune compromise, neutropenia, severe infection, small peaks, and short exposure. It should not be used to justify wide intervals in neutropenic patients, endocarditis or other sites where host defences are limited. It does not replace measured levels in toxic drugs.

Risks. Over-reliance on the PAE can cause under-treatment: stretching intervals beyond the validated schedule increases the risk of regrowth and resistance, especially with organisms at high MIC.

Monitoring. Follow validated dosing schedules and levels for aminoglycosides, vancomycin and others; clinical response and microbiological clearance; renal function.

Special groups. Neutropenia: use continuous or more frequent dosing of beta-lactams, since PAE and immune enhancement are unreliable. Critical illness and high inoculum: use higher exposure rather than longer intervals. Pregnancy and children: usual weight-based schedules apply. Region: where assays are unavailable, conservative once-daily aminoglycoside dosing with attention to renal function is the practical approach.